Amicus Therapeutics FOLD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Amicus Therapeutics (FOLD) Business Model and Operations Summary
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Key Insights
Amicus Therapeutics (FOLD) Core Market Data and Business Metrics
Latest Closing Price
$7.95Market Cap
$2.44 BillionPrice-Earnings Ratio
-23.38Total Outstanding Shares
307.24 Million SharesTotal Employees
499Dividend
No dividendIPO Date
May 31, 2007SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
47 Hulfish Street, Princeton, NJ, 08542
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-18.41 Million |
| Net Cash Flow From Investing Activities, Continuing | $-4.13 Million |
| Exchange Gains/Losses | $-11.04 Million |
| Net Cash Flow From Financing Activities | $12.23 Million |
| Net Cash Flow From Operating Activities | $-26.52 Million |
| Net Cash Flow | $-29.45 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Income/Loss | $5.21 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Diluted Average Shares | $913.22 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Net Income/Loss Available To Common Stockholders, Basic | $-104.69 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $31.74 Million |
| Comprehensive Income/Loss Attributable To Parent | $-72.95 Million |
| Comprehensive Income/Loss | $-72.95 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $31.74 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Long-term Debt | $389.49 Million |
| Noncurrent Liabilities | $449.59 Million |
| Current Assets | $498.47 Million |
| Equity | $178.82 Million |
| Liabilities And Equity | $786.56 Million |
| Intangible Assets | $18.03 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||